Greek study to measure daily life impact of iron overload drug
NCT ID NCT07352878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how thalassemia patients in Greece feel day-to-day while taking a standard iron-removing medicine called deferasirox. Researchers will survey 150 adults to measure their physical and mental well-being. The goal is to understand real-world quality of life, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA MAJOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Could a simple exercise routine strengthen bones in thalassemia?
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- New stem cell processing method offers hope for patients without a perfect donor match
- Mismatched donor stem cell transplant could widen treatment access for sickle cell disease